Interleukin-33 Involvement in Nonsmall Cell Lung Carcinomas: An Update

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Lung carcinogenesis involves genetic and epigenetic changes, influenced by non-neoplastic cells.
• Tumor-associated inflammatory pathways significantly impact cancer development.
• Interleukin-33 (IL-33) is an IL-1-like alarmin with a dual role in immunity and gene transcription.

Purpose of the Study:

• To review the dual role of Interleukin-33 (IL-33) in lung carcinogenesis.
• To discuss the emerging role of the IL-33/ST2 axis in modulating the tumor microenvironment (TME).
• To explore the potential of IL-33 as a therapeutic target in lung cancer.

Main Methods:

• Literature review focusing on Interleukin-33 (IL-33) and its receptor ST2.
• Analysis of studies investigating the IL-33/ST2 axis in the context of lung cancer.
• Synthesis of information on IL-33's immunomodulatory and transcriptional functions in tumorigenesis.

Main Results:

• The IL-33/ST2 axis acts as a potent modulator of the tumor microenvironment (TME).
• IL-33 can recruit immune cells, influence TME composition, promote malignant proliferation, or enhance antitumor immunity.
• The precise role of IL-33 in lung tumorigenesis remains under investigation but shows significant potential.

Conclusions:

• The IL-33/ST2 axis is a critical factor in lung cancer progression and immune response.
• Understanding IL-33's functions offers insights into novel therapeutic strategies for lung cancer.
• Targeting the IL-33/ST2 pathway presents a promising avenue for lung cancer treatment.